| Ad Title: |
Cancer of the Uterus |
| Study Title: |
GOG #0230-B: A Phase II Evaluation of Thalidomide (NSC#66847, IND#48832) in the Treatment of Persistent or Recurrent Carcinosarcoma of the Uterus |
| Protocol Number: |
0103-081 |
| Department(s) involved in the Study: |
Gynecology, Obstetrics & Gynecology, Simmons Comprehensive Cancer Center
|
| Purpose of the Study: |
To evaluate the effectiveness and side effects of the experimental drug Thalidomide in the treatment of patients with uterine cancer. |
| Participant Eligibility: |
Patients should have recovered from the effects of recent surgery, radiotherapy or chemotherapy. |
| Disease/Condition Under Study: |
Cancer of the uterus |
| Cancer Related Study: |
No
|
| Study Drug(s): |
Thalidomide-Thalomid
|
| Study Device(s): |
|
| Study Doctor: |
Dr. David Miller |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Parkland Memorial Hospital
|
Yes
|
|
UT Southwestern University Hospitals St. Paul Building
|
Yes
|
|
UT Southwestern University Hospitals Zale Lipshy Building
|
Yes
|
|
Aston Ambulatory Care Center
|
Yes
|
|
| Contact Phone: |
214_648_6753 |
| Email: |
Paula.Honea@utsouthwestern.edu |
| Other Information: |
This is a Gynecologic Oncology Group sponsored trial. |
| Website Keywords: |
Gyn Oncology, Gynecology, Women's Health
|
| Medical Keywords: |
cancer
|
